Home/Pipeline/CathHELIX Transcatheter Mitral Repair System

CathHELIX Transcatheter Mitral Repair System

Mitral Valve Regurgitation (likely degenerative)

Pre-clinical / Early ClinicalActive

Key Facts

Indication
Mitral Valve Regurgitation (likely degenerative)
Phase
Pre-clinical / Early Clinical
Status
Active
Company

About HVR Cardio

HVR Cardio is a private, clinical-stage medical device company pioneering a transcatheter mitral valve repair system called CathHELIX. Its proprietary HELIX technology is designed to perform a percutaneous annuloplasty, addressing the root cause of mitral regurgitation (annular dilation) by deploying a self-securing ring. The company is led by an experienced team with deep roots in structural heart innovation and is supported by a strong clinical advisory board. HVR Cardio is positioned to address a large, underserved market of patients with degenerative mitral regurgitation who are unsuitable for or seek alternatives to open-heart surgery.

View full company profile

Therapeutic Areas